Caplin Point Laboratories Limited (CAPLIPOINT.NS)
- Previous Close
1,901.80 - Open
1,851.00 - Bid --
- Ask --
- Day's Range
1,836.70 - 1,880.00 - 52 Week Range
1,225.00 - 2,641.00 - Volume
62,202 - Avg. Volume
140,481 - Market Cap (intraday)
141.45B - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
27.63 - EPS (TTM)
67.36 - Earnings Date May 15, 2025
- Forward Dividend & Yield 5.00 (0.27%)
- Ex-Dividend Date Sep 23, 2024
- 1y Target Est
2,472.00
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
www.caplinpoint.net3,406
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: CAPLIPOINT.NS
View MorePerformance Overview: CAPLIPOINT.NS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CAPLIPOINT.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CAPLIPOINT.NS
View MoreValuation Measures
Market Cap
141.94B
Enterprise Value
133.23B
Trailing P/E
27.59
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.60
Price/Book (mrq)
5.56
Enterprise Value/Revenue
7.12
Enterprise Value/EBITDA
18.71
Financial Highlights
Profitability and Income Statement
Profit Margin
27.26%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
18.9B
Net Income Avi to Common (ttm)
5.15B
Diluted EPS (ttm)
67.36
Balance Sheet and Cash Flow
Total Cash (mrq)
8.27B
Total Debt/Equity (mrq)
0.09%
Levered Free Cash Flow (ttm)
--